Research combining KRAS-specific siRNAs with miR-34, a tumor-suppressor microRNA, showed reduced tumor growth and increased sensitivity to cisplatin in vitro and in vivo using KRAS-p53 mutated mouse models of lung adenocarcinoma [36]. This evidence concerns the gene KRAS and lung adenocarcinoma.